Sarepta Therapeutics, Inc. Quarterly Revenues in USD from Q4 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Summary
Sarepta Therapeutics, Inc. quarterly/annual Revenues history and growth rate from Q4 2016 to Q3 2024.
  • Sarepta Therapeutics, Inc. Revenues for the quarter ending September 30, 2024 was $467M, a 40.8% increase year-over-year.
  • Sarepta Therapeutics, Inc. Revenues for the twelve months ending September 30, 2024 was $1.64B, a 48.5% increase year-over-year.
  • Sarepta Therapeutics, Inc. annual Revenues for 2023 was $1.24B, a 33.3% increase from 2022.
  • Sarepta Therapeutics, Inc. annual Revenues for 2022 was $933M, a 32.9% increase from 2021.
  • Sarepta Therapeutics, Inc. annual Revenues for 2021 was $702M, a 30% increase from 2020.
Revenues, Trailing 12 Months (USD)
Revenues, Quarterly (USD)
Revenues, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.64B $467M +$135M +40.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $1.5B $363M +$102M +38.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $1.4B $413M +$160M +63.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-01
Q4 2023 $1.24B $397M +$138M +53.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $1.1B $332M +$102M +44.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $1B $261M +$27.8M +11.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $976M $254M +$42.7M +20.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 $933M $258M +$57M +28.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $876M $230M +$40.9M +21.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 $835M $233M +$69.4M +42.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $766M $211M +$63.9M +43.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q4 2021 $702M $201M +$56.3M +38.8% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $646M $189M +$45.5M +31.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 $600M $164M +$26.7M +19.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-02
Q1 2021 $573M $147M +$33.3M +29.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $540M $145M +$45M +45% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 $495M $144M +$44.9M +45.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $450M $137M +$42.7M +45.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $407M $114M +$26.7M +30.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $381M $100M +$15.7M +18.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 $365M $99M +$20.6M +26.2% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 $345M $94.7M +$21.1M +28.7% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 $323M $87M +$22.4M +34.7% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 $301M $84.4M +$27.1M +47.4% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-26
Q3 2018 $274M $78.5M +$32.5M +70.8% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-26
Q2 2018 $241M $73.5M +$38.5M +110% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-26
Q1 2018 $203M $64.6M +$48.3M +295% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-26
Q4 2017 $155M $57.3M +$51.9M +957% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 $103M $46M Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 $35M Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 $16.3M Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 $5.42M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.